HOME >> BIOLOGY >> NEWS
Actonel significantly reduced moderate and severe vertebral fractures

San Antonio, TX (September 20, 2002) A new analysis of scientific data presented at today's meeting of the American Society for Bone and Mineral Research (ASBMR) showed that a 5 mg dose of Actonel (risedronate sodium tablets) daily significantly reduced moderate and severe vertebral fracture risk by 70 percent within one year in postmenopausal women with osteoporosis. Furthermore, the significant effect on vertebral fracture risk was sustained over three years.

This analysis combined data from two large Actonel clinical trials, VERT-NA and VERT-MN, which included postmenopausal women with either one prevalent vertebral fracture and low bone mineral density (BMD), or with at least two prevalent vertebral fractures. The objective of this analysis was to compare the incidence of moderate or severe vertebral fracture at one year in women who received Actonel or placebo. Fracture severity was determined using the fracture severity scoring system developed by Harry Genant, M.D., Professor of Radiology, Medicine, Epidemiology and Orthopaedic Surgery at the University of California, San Francisco, an investigator and pioneer of the assessment method used in the analysis.

Recent studies show severity of prevalent vertebral fractures is a predictor of future vertebral and non-vertebral fracture risk; patients with more severe baseline vertebral fractures are more likely to experience subsequent vertebral and non-vertebral fractures. Therefore, reducing the incidence of moderate or severe vertebral fractures may help decrease the risk of future fractures.

"The ultimate goal of osteoporosis treatment is to prevent fractures," said Dr. Genant, "These new findings, combined with previous Actonel clinical data showing reductions in both risk of first vertebral fracture and multiple vertebral fractures, suggest that Actonel reduces fracture risk across a range of osteoporotic severity."

According to
'"/>


20-Sep-2002


Page: 1 2 3 4

Related biology news :

1. Rare mutations can significantly increase risk factor for heart disease
2. Cancer health risk significantly underestimated by EPAs ambient model estimates
3. Double mastectomies significantly lower risk of breast cancer in women who are genetically at risk
4. HAART therapy significantly prolongs survival in AIDS patients with central nervous system lymphoma
5. ENBREL rapidly, significantly improved back pain, mobility, function in ankylosing spondylitis
6. Once weekly ENBREL significantly reduced rheumatoid arthritis pain, inflammation & improved function
7. Cognitive abilities increase significantly with time in most prematurely born children
8. Combining key ingredients of vegetarian diet cuts cholesterol significantly, says study
9. Pollen productionand allergiesmay rise significantly over next 50 years
10. Brain size in premature infants significantly smaller than full-term babies
11. Multicenter study shows Benecol spread significantly reduces cholesterol levels in patients taking statin drugs

Post Your Comments:
(Date:7/23/2015)... , July 23, 2015 Research ... addition of the "Global Outlook of the ... offering. The global biometrics market ... public and commercial applications owing to the uptake ... witness a transformation that enhances the growth of ...
(Date:7/13/2015)... 13, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced sampling of ClearPad ® ... integration (TDDI) product targeting smartphones and tablets. This ... Synaptics , best-in-class touch controller IP and ... developed in the company,s Japan Design Center. TDDI ...
(Date:7/9/2015)... , July 9, 2015  Synaptics ... developer of human interface solutions, today announced ... industry,s first fully hardware encapsulated fingerprint sensor ... authentication technology is literally off the grid, ... biometric matching within the fingerprint sensor to ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
(Date:7/29/2015)... ... July 29, 2015 , ... ... announced its GHS Label Guide . To align chemical container labeling with ... guide includes explanations of label components, an example of an accurate label, and ...
(Date:7/29/2015)... , July 29, 2015  Therapath Neuropathology ... announces increased partnerships with VA and Military Medical ... Nerve Fiber Density (ENFD) and Sweat Gland Nerve ... fiber neuropathy ( https://therapath.com/skin ). ... Fiber Density (ENFD) on punch skin biopsy is ...
(Date:7/29/2015)... SLOUGH, England , July 29, 2015  Indivior ... Application (NDA) for naloxone nasal spray was accepted and ... Administration (FDA) for the treatment of opioid overdose. This ... contains naloxone specially formulated for optimal absorption into the ... to require minimal training so individuals may be better ...
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... medicine company, is pleased to announce that the final ... have been locked.  Prototypes for industrial and regulatory ... an application for CE mark clearance to market ... in 2016. (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  ...
Breaking Biology Technology:Brady Announces a New GHS Label Guide 2Neuropathology services for VA and Military health systems 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5
Cached News: